4/A: Candel Therapeutics Executive Seshu Tyagarajan Executes Stock Option and Sells Shares Under 10b5-1 Plan

Seshu Tyagarajan, Chief Technology Officer of Candel Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• On March 17, 2025, Seshu Tyagarajan, the Chief Technology Officer of Candel Therapeutics, exercised a stock option to acquire 20,000 shares of common stock at a price of $1.29 per share.
• On the same day, Tyagarajan sold 31,278 shares of common stock at a weighted average price of $8.8224 per share, with prices ranging from $8.67 to $9.00.
• These transactions were executed under a 10b5-1 trading plan adopted on November 15, 2024.
• Following these transactions, Tyagarajan directly owns 85,512 shares of Candel Therapeutics common stock and holds options for 70,000 shares.
• This Form 4/A is an amendment to a previous filing to include the acquisition of shares underlying stock options, which was initially omitted.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of insider trading activity. The transactions are part of a pre-arranged plan, suggesting no particular bullish or bearish sentiment.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of insider transactions. It is common for executives to utilize 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information. The sale represents a small percentage of the overall shares outstanding.

Comparison to Industry Standards

• Executive compensation packages often include stock options as a form of long-term incentive.
• The use of 10b5-1 trading plans is a standard practice among corporate executives to manage their stock holdings and comply with insider trading regulations.
• Comparing the volume of shares sold to the total outstanding shares of Candel Therapeutics would provide context on the significance of this transaction.
• Similar transactions can be observed in filings from executives at comparable biotechnology companies such as BioNTech, Moderna, and Gilead Sciences.

Stakeholder Impact

• The sale of shares by an executive could be perceived negatively by some investors, but the existence of a 10b5-1 plan mitigates this concern.
• The transactions have a minimal impact on employees, customers, suppliers, and creditors.

Key Dates

Keywords

Candel Therapeutics, Seshu Tyagarajan, Stock Options, Form 4, 10b5-1 Trading Plan, Insider Trading, CADL, Share Sale, Equity, Amendment